Stock Screener App

무료 -

1.66

3.11% +0.05

ATAI Life Sciences N.V. (ATAI)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

ATAI Life Sciences N.V. 주식(ATAI)의 최신 뉴스

Investor's Delight: ATAI Life Sciences N.V. (ATAI) Closes Weak at 1.61, Down -1.23 – DWinneX - The Dwinnex

ATAI: Enormous Potential Upside But No Clarity Yet (NASDAQ:ATAI) - Seeking Alpha

ATAI Life Sciences N.V. [ATAI] Shares Fall -2.40 % on Thursday – Knox Daily - Knox Daily

ATAI Life Sciences N.V. (ATAI) Price Target Increased by 5.04% to 12.57 - MSN

atai Life Sciences bolsters board with two new directors - Proactive Investors USA

Proactive Investors USA

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors - Investing News Network

Investing News Network

You might want to take a look at ATAI Life Sciences N.V. (ATAI) now – Sete News - SETE News

It would be worthwhile to take a closer look at ATAI Life Sciences N.V. (ATAI) – US Post News - US Post News

Analysts review ATAI Life Sciences N.V.'s rating – Knox Daily - Knox Daily

Balance Sheet Dive: ATAI Life Sciences N.V. (ATAI)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX - The Dwinnex

Atai Life Sciences CEO sells shares worth $290,501 By Investing.com - Investing.com

Atai Life Sciences CEO sells shares worth $290,501 By Investing.com - Investing.com Canada

Investing.com Canada

ATAI’s Financial Health: Exploring ATAI Life Sciences N.V.’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle

The InvestChronicle

7 Best Psychedelic Stocks to Watch - MSN

Perhaps timely catching ATAI Life Sciences N.V. (ATAI) would be a good idea – Sete News - SETE News

ATAI Life Sciences N.V. [NASDAQ: ATAI] Sees Increase in Stock Value – Knox Daily - Knox Daily

atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe - Proactive Investors USA

Proactive Investors USA

Atai Life Sciences promotes Srinivas Rao to Co-EO - TipRanks.com - TipRanks

ATAI Life Sciences N.V. (ATAI) Stock: A Year of Declines and Increases - The InvestChronicle

The InvestChronicle

atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe - Proactive Investors USA

Proactive Investors USA

atai Life Sciences co-founder takes on CEO role after better quarter - Proactive Investors USA

Proactive Investors USA

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates - GlobeNewswire

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates - Yahoo Finance

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates - GlobeNewswire

ATAI Life's Schizophrenia Candidate Shows Promising Action In Mid-Stage Study - AOL

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

GlobeNewswire Inc.

atai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression study - Proactive Investors USA

Proactive Investors USA

Market Recap Check: ATAI Life Sciences N.V. (ATAI)'s Negative Finish at 1.85, Up/Down -3.14 – DWinneX - The Dwinnex

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

GlobeNewswire Inc.

What is the investor's view on ATAI Life Sciences N.V. (ATAI)? – US Post News - US Post News

atai Life Sciences outlines key milestones in psychedelic therapy for depression in 2023 and 2024 - Proactive Investors UK

Proactive Investors UK

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice

Zacks Investment Research

Atai Life Sciences' executive sells $66k in company stock - Investing.com

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On We - Benzinga

Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Where Will ATAI Life Sciences NV (ATAI) Stock Go Next After It Is Up 12.88% in a Week? - InvestorsObserver

InvestorsObserver

Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St

Atai Life announces initial results from Psytech's Phase 2a study of BPL-003 - TipRanks.com - TipRanks

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

GlobeNewswire Inc.

atai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapies - Proactive Investors USA

Proactive Investors USA

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

GlobeNewswire Inc.

Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Atai Life Sciences advances VLS-01 for treatment-resistant depression - Marketscreener.com

Marketscreener.com

MindMed’s stock soars 51.5% after FDA grants breakthrough designation to LSD therapy for a form of anxiety

MindMed’s stock soars 58% after FDA grants breakthrough designation to LSD therapy for a form of anxiety

MindMed’s stock jumps 24% after FDA grants breakthrough designation to LSD therapy

MindMed’s stock jumps 24% after FDA grants breakthrough designation to LSD therapy

$74.43

1.44%

$153.11

0.26%

$28.01

0.04%

$150.06

1.56%

$366.34

0.20%

$94.10

2.94%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기